- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03157336
Cassava Intervention Project
June 3, 2022 updated by: Desire Tshala-Katumbay, Ministry of Public Health, Democratic Republic of the Congo
Toxicodietary and Genetic Determinants of Susceptibility to Neurodegeneration
Investigators will implement a novel cassava processing method (wetting method, WTM) that safely removes cyanogenic compounds from cassava flour prior to human consumption in a stratified village-cluster randomized non-inferiority trial so as to compare the effectiveness of a peer-led intervention (women training other women in the WTM) with that by community-health worker specialists.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The proposed project seeks methods to prevent and elucidate biomarkers of neurocognition and motor deficits associated with chronic dietary reliance on cyanogenic cassava, a staple food crop for more than 600 millions of people living in the tropics.
Aim 1 will implement a novel cassava processing method (wetting method, WTM) that safely removes cyanogenic compounds from cassava flour prior to human consumption in a stratified village-cluster randomized non-inferiority trial so as to compare the effectiveness of a peer-led intervention (women training other women in the WTM) with that by community-health worker specialists (2 intervention training arms).
Aim 2 will determine whether post-intervention reductions in cassava cyanogenic content and child U-SCN are associated with changes in biomarkers of cassava neurotoxicity particularly 8,12-iso-iPF2α-VI isoprostane (oxidant marker), carbamoylated albumin fragments KVPQVSTPTLVEVSR (residues 438-452) and LDELRDEGKASSAK (residues 206-219), or homocitrulline (carbamoylating markers), and scores at the KABC-II cognition and BOT-2 motor testing.
Study Type
Interventional
Enrollment (Actual)
1200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kinshasa, Congo, The Democratic Republic of the
- INRB
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 12 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Households with a konzo child and non-konzo sibling between 5 and 12 years
- Presence of a biological mother primarily responsible for the household food preparation and caring for the children
- Mother consenting to participate in this study
Exclusion Criteria:
- History of seizures
- History of cerebral malaria
- History of retroviral (HIV-HTLV) infections
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Peer-led Intervention
Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
|
The intervention will implement the WTM cassava processing technique in participating households.
Twenty women (in leading roles) will be our principal candidates to serve as peer trainers.
Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method.
Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families.
Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be < 10 ppm as per the recommendations of the World Health Organization.
|
EXPERIMENTAL: Specialist-led Intervention
Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
|
The intervention will implement the WTM cassava processing technique in participating households.
Twenty women (in leading roles) will be our principal candidates to serve as peer trainers.
Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method.
Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families.
Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be < 10 ppm as per the recommendations of the World Health Organization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in food cyanogenic exposure
Time Frame: From baseline to 6-month time points
|
Cassava cyanogenic content
|
From baseline to 6-month time points
|
Change in internal cyanogenic exposure
Time Frame: From baseline to 6-month time points
|
Urinary concentrations of thiocyanate (U-SCN)
|
From baseline to 6-month time points
|
Change in oxidation damage
Time Frame: From baseline to 6-month time points
|
Serum isoprostanes
|
From baseline to 6-month time points
|
Change in carbamoylation
Time Frame: From baseline to 6-month time points
|
serum albumin peptidic carbamoylation
|
From baseline to 6-month time points
|
Change in carbamoylation surrogate
Time Frame: From baseline to 6-month time points
|
serum homocitrulline
|
From baseline to 6-month time points
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognition performance
Time Frame: From baseline to 6-month time points
|
Kaufman Assessment Battery for Children (KABC-II) for cognition testing score
|
From baseline to 6-month time points
|
Change in motor proficiency
Time Frame: From baseline to 6-month time points
|
Motor proficiency Bruininks/Oseretsky Testing (BOT-2) score
|
From baseline to 6-month time points
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Mumba Ngoyi, Ministry of Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 30, 2017
Primary Completion (ACTUAL)
June 1, 2022
Study Completion (ACTUAL)
June 1, 2022
Study Registration Dates
First Submitted
May 12, 2017
First Submitted That Met QC Criteria
May 15, 2017
First Posted (ACTUAL)
May 17, 2017
Study Record Updates
Last Update Posted (ACTUAL)
June 6, 2022
Last Update Submitted That Met QC Criteria
June 3, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FWA00017202
- R01ES019841 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurotoxicity Syndrome, Cassava
-
zhang shoulongChanghai Hospital; Jinan Military General HospitalRecruitingImmune Effector Cell Associated Neurotoxicity SyndromeChina
-
National Cheng-Kung University HospitalActive, not recruitingNeurotoxicity SyndromesTaiwan
-
Assaf-Harofeh Medical CenterInternational Diabetes Federation; Israeli MOHWithdrawn
-
University Hospital, MontpellierRecruitingLymphoma, B-Cell | NeurotoxicityFrance
-
Jack KhouriNot yet recruitingMultiple Myeloma | Refractory Multiple Myeloma | Cytokine Release Syndrome | Immune Effector Cell Associated Neurotoxicity SyndromeUnited States
-
Seoul National University HospitalActive, not recruitingAnesthesia and NeurotoxicityKorea, Republic of
-
Universitas Sumatera UtaraCompleted
-
Baylor College of MedicineCompletedSeizures | Development Delay | Anesthetic NeurotoxicityUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingNeurotoxicityUnited States
-
University of Medicine and Dentistry of New JerseyTerminatedNeurotoxicity SyndromesUnited States
Clinical Trials on Non Inferiority WTM Interventional Trial
-
University College, LondonRoyal Free Hospital NHS Foundation TrustRecruitingTracheostomyUnited Kingdom
-
Basilea PharmaceuticaCompletedAcute Myeloid LeukemiaGermany
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Canadian Lung Association/British... and other collaboratorsCompleted
-
Otto-Friedrich-University BambergDepartment of Psychosomatic Medicine, LWL University Hospital BochumCompletedWeight Loss | Overweight and Obesity | GenderGermany
-
Medical University of WarsawChildren's Memorial Health Institute, PolandUnknown
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States